🚀 VC round data is live in beta, check it out!
Maze Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Maze Therapeutics and similar public comparables like Eczacıbaşı İlaç, Bio-Thera Solutions, SOTHEMA, Corvus Pharma and more.
Maze Therapeutics Overview
About Maze Therapeutics
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Founded
2017
HQ
Employees
125
Website
Sectors
Financials (LTM)
EV
$1B
Maze Therapeutics Financials
Maze Therapeutics reported last 12-month revenue of $4M and negative EBITDA of ($146M).
In the same LTM period, Maze Therapeutics generated $4M in gross profit, ($146M) in EBITDA losses, and had net loss of ($136M).
Revenue (LTM)
Maze Therapeutics P&L
In the most recent fiscal year, Maze Therapeutics reported revenue of — and EBITDA of ($140M).
Maze Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $4M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($146M) | XXX | ($140M) | XXX | XXX | XXX |
| EBITDA Margin | (3941%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (3970%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($136M) | XXX | ($131M) | XXX | XXX | XXX |
| Net Margin | (3680%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Maze Therapeutics Stock Performance
Maze Therapeutics has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Maze Therapeutics' stock price is $28.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 4.6% | XXX | XXX | XXX | $-2.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMaze Therapeutics Valuation Multiples
Maze Therapeutics trades at 291.5x EV/Revenue multiple, and (7.4x) EV/EBITDA.
EV / Revenue (LTM)
Maze Therapeutics Financial Valuation Multiples
As of April 18, 2026, Maze Therapeutics has market cap of $1B and EV of $1B.
Equity research analysts estimate Maze Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maze Therapeutics has a P/E ratio of (10.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 291.5x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (7.4x) | XXX | (7.7x) | XXX | XXX | XXX |
| EV/EBIT | (7.3x) | XXX | (7.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 291.5x | XXX | — | XXX | XXX | XXX |
| P/E | (10.3x) | XXX | (10.7x) | XXX | XXX | XXX |
| EV/FCF | (8.6x) | XXX | (9.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Maze Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Maze Therapeutics Margins & Growth Rates
Maze Therapeutics' revenue in the last 12 month grew by 188%.
Maze Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Maze Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 188% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (3941%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 927% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3069% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Maze Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Maze Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eczacıbaşı İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Thera Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| SOTHEMA | XXX | XXX | XXX | XXX | XXX | XXX |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Precigen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maze Therapeutics M&A Activity
Maze Therapeutics acquired XXX companies to date.
Last acquisition by Maze Therapeutics was on XXXXXXXX, XXXXX. Maze Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Maze Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMaze Therapeutics Investment Activity
Maze Therapeutics invested in XXX companies to date.
Maze Therapeutics made its latest investment on XXXXXXXX, XXXXX. Maze Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Maze Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Maze Therapeutics
| When was Maze Therapeutics founded? | Maze Therapeutics was founded in 2017. |
| Where is Maze Therapeutics headquartered? | Maze Therapeutics is headquartered in United States. |
| How many employees does Maze Therapeutics have? | As of today, Maze Therapeutics has over 125 employees. |
| Who is the CEO of Maze Therapeutics? | Maze Therapeutics' CEO is Jason V. Coloma. |
| Is Maze Therapeutics publicly listed? | Yes, Maze Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Maze Therapeutics? | Maze Therapeutics trades under MAZE ticker. |
| When did Maze Therapeutics go public? | Maze Therapeutics went public in 2025. |
| Who are competitors of Maze Therapeutics? | Maze Therapeutics main competitors are Eczacıbaşı İlaç, Bio-Thera Solutions, SOTHEMA, Corvus Pharma. |
| What is the current market cap of Maze Therapeutics? | Maze Therapeutics' current market cap is $1B. |
| What is the current revenue of Maze Therapeutics? | Maze Therapeutics' last 12 months revenue is $4M. |
| What is the current revenue growth of Maze Therapeutics? | Maze Therapeutics revenue growth (NTM/LTM) is 188%. |
| What is the current EV/Revenue multiple of Maze Therapeutics? | Current revenue multiple of Maze Therapeutics is 291.5x. |
| Is Maze Therapeutics profitable? | No, Maze Therapeutics is not profitable. |
| What is the current EBITDA of Maze Therapeutics? | Maze Therapeutics has negative EBITDA and is not profitable. |
| What is Maze Therapeutics' EBITDA margin? | Maze Therapeutics' last 12 months EBITDA margin is (3941%). |
| What is the current EV/EBITDA multiple of Maze Therapeutics? | Current EBITDA multiple of Maze Therapeutics is (7.4x). |
| What is the current FCF of Maze Therapeutics? | Maze Therapeutics' last 12 months FCF is ($126M). |
| What is Maze Therapeutics' FCF margin? | Maze Therapeutics' last 12 months FCF margin is (3409%). |
| What is the current EV/FCF multiple of Maze Therapeutics? | Current FCF multiple of Maze Therapeutics is (8.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.